Sensus Gains China Approval of Radiation Device for Keloids

The CFDA approved a superficial radiation therapy device made by Sensus Healthcare of the US to treat and prevent keloids. Keloids are raised scars formed from benign fibrous tissue. Sensus' SRT-100™ device is based on a proprietary low-energy x-ray technology. Chindex Medical, a medical device distributor owned by Fosun Pharma, has been distributing the SRT-100 device in China for non-melanoma skin cancers since 2014. It plans to emphasize use of the device to prevent keloids associated with Cesarean sections. More details.... Stock Symbols: (NSDQ: SRTS) (SHA: 600196; HK: 2196) Share this with colleagues: // //